Reported 1 day ago
Trevi Therapeutics Inc. (NASDAQ:TRVI) is highlighted as a promising investment by Morgan Stanley, with an Overweight rating and an $18 price target. The optimism is driven by Haduvio, an innovative treatment for chronic cough that addresses significant patient needs in a market with limited effective alternatives. Analyst Judah Frommer suggests Haduvio could generate multi-billion dollar opportunities, supported by increasing interest from major pharmaceutical companies.
Source: YAHOO